CCR 20th Anniversary Commentary: Molecular Pathology of ALK-Rearranged Lung Tumors.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26626570.
- Also identified by DOI 10.1158/1078-0432.CCR-14-3130.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The article by Rodig and colleagues, which was published in the August 15, 2009, issue of Clinical Cancer Research, helped detail the clinicopathologic profile of ALK-positive tumors and initiated the development of ALK diagnostics. Subsequent clinical trials utilized these findings, resulting in the approval of effective targeted therapies. The ALK story is a model for the development of therapies in the genomic era.
Medical subject headings
- Adenocarcinoma
- Lung Neoplasms
- Protein-Tyrosine Kinases